Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,28747995,Ki,"Considering a typical dosing regimen and applying the obtained Ki values of 0.72 µM (darifenacin, 15 mg daily) and 7.2 µM [propiverine, 30 mg daily, immediate release (IR)] for the inhibition of CYP2D6 yielded a predicted 1.9-fold and 1.4-fold increase in the area under the curve (AUC) of debrisoquine (CYP2D6 substrate), respectively.",Assessment of inhibitory effects on major human cytochrome P450 enzymes by spasmolytics used in the treatment of overactive bladder syndrome. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28747995/),μM,0.72,620,DB01036,Tolterodine
,28747995,Ki,"Considering a typical dosing regimen and applying the obtained Ki values of 0.72 µM (darifenacin, 15 mg daily) and 7.2 µM [propiverine, 30 mg daily, immediate release (IR)] for the inhibition of CYP2D6 yielded a predicted 1.9-fold and 1.4-fold increase in the area under the curve (AUC) of debrisoquine (CYP2D6 substrate), respectively.",Assessment of inhibitory effects on major human cytochrome P450 enzymes by spasmolytics used in the treatment of overactive bladder syndrome. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28747995/),μM,7.2,621,DB01036,Tolterodine
,28747995,Ki,"Due to the inhibition of the particular intestinal CYP3A4, the obtained Ki values of 14 µM of propiverine (30 mg daily, IR) resulted in a predicted doubling of the AUC for midazolam (CYP3A4 substrate).",Assessment of inhibitory effects on major human cytochrome P450 enzymes by spasmolytics used in the treatment of overactive bladder syndrome. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28747995/),μM,14,622,DB01036,Tolterodine
,19000553,time to reach Cmax,"CYP2D6 status had no effect on time to reach Cmax (5 h), renal clearance (approximately 250 ml/min), or half-life (approximately 8 h).",Pharmacokinetic profile of fesoterodine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000553/),h,5,17511,DB01036,Tolterodine
,19000553,renal clearance,"CYP2D6 status had no effect on time to reach Cmax (5 h), renal clearance (approximately 250 ml/min), or half-life (approximately 8 h).",Pharmacokinetic profile of fesoterodine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000553/),[ml] / [min],250,17512,DB01036,Tolterodine
,19000553,half-life,"CYP2D6 status had no effect on time to reach Cmax (5 h), renal clearance (approximately 250 ml/min), or half-life (approximately 8 h).",Pharmacokinetic profile of fesoterodine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000553/),h,8,17513,DB01036,Tolterodine
,9247842,time to peak serum concentration,Tolterodine was rapidly absorbed following oral administration (time to peak serum concentration 0.9 +/- 0.4 h).,Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9247842/),h,0.9,23438,DB01036,Tolterodine
,9247842,absolute bioavailability,"The absolute bioavailability was highly variable, ranging from 10 to 70%.",Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9247842/),%,10 to 70,23439,DB01036,Tolterodine
,9247842,volume of distribution at steady-state,"The volume of distribution at steady-state ranged from 0.9 to 1.6 l/kg and systemic clearance ranged from 0.23 to 0.52 l/h/kg, which resulted in a terminal half-life of 2-3 h.",Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9247842/),[l] / [kg],0.9 to 1.6,23440,DB01036,Tolterodine
,9247842,systemic clearance,"The volume of distribution at steady-state ranged from 0.9 to 1.6 l/kg and systemic clearance ranged from 0.23 to 0.52 l/h/kg, which resulted in a terminal half-life of 2-3 h.",Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9247842/),[l] / [h·kg],0.23 to 0.52,23441,DB01036,Tolterodine
,9247842,terminal half-life,"The volume of distribution at steady-state ranged from 0.9 to 1.6 l/kg and systemic clearance ranged from 0.23 to 0.52 l/h/kg, which resulted in a terminal half-life of 2-3 h.",Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9247842/),h,2-3,23442,DB01036,Tolterodine
,9247842,excretion,"Following oral administration of (14C)-tolterodine, the excretion of radioactivity into urine and feces was 77 +/- 4.0% and 17 +/- 3.5%, respectively.",Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9247842/),%,77,23443,DB01036,Tolterodine
,9247842,excretion,"Following oral administration of (14C)-tolterodine, the excretion of radioactivity into urine and feces was 77 +/- 4.0% and 17 +/- 3.5%, respectively.",Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9247842/),%,17,23444,DB01036,Tolterodine
,19915829,AUC(infinity) 5-HMT,"Mean AUC(infinity) 5-HMT values were 47.9 and 51.4 ng h/mL for nighttime and daytime dosing, respectively; the mean time to reach maximum concentration (C(max)) values were 3.9 and 5.0 ng/mL, respectively.",The pharmacokinetic profile of fesoterodine 8 mg with daytime or nighttime dosing. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19915829/),[h·ng] / [ml],47.9,52057,DB01036,Tolterodine
,19915829,AUC(infinity) 5-HMT,"Mean AUC(infinity) 5-HMT values were 47.9 and 51.4 ng h/mL for nighttime and daytime dosing, respectively; the mean time to reach maximum concentration (C(max)) values were 3.9 and 5.0 ng/mL, respectively.",The pharmacokinetic profile of fesoterodine 8 mg with daytime or nighttime dosing. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19915829/),[h·ng] / [ml],51.4,52058,DB01036,Tolterodine
,19915829,time to reach maximum concentration (C(max)),"Mean AUC(infinity) 5-HMT values were 47.9 and 51.4 ng h/mL for nighttime and daytime dosing, respectively; the mean time to reach maximum concentration (C(max)) values were 3.9 and 5.0 ng/mL, respectively.",The pharmacokinetic profile of fesoterodine 8 mg with daytime or nighttime dosing. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19915829/),[ng] / [ml],3.9,52059,DB01036,Tolterodine
,19915829,time to reach maximum concentration (C(max)),"Mean AUC(infinity) 5-HMT values were 47.9 and 51.4 ng h/mL for nighttime and daytime dosing, respectively; the mean time to reach maximum concentration (C(max)) values were 3.9 and 5.0 ng/mL, respectively.",The pharmacokinetic profile of fesoterodine 8 mg with daytime or nighttime dosing. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19915829/),[ng] / [ml],5.0,52060,DB01036,Tolterodine
,19915829,time to reach maximum concentration (T(max)),"The median time to reach maximum concentration (T(max)) was 5.0 h for both dosing regimens, and the mean terminal elimination half-life (T((1/2))) was 5.9 and 5.7 h for nighttime and daytime dosing, respectively.",The pharmacokinetic profile of fesoterodine 8 mg with daytime or nighttime dosing. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19915829/),h,5.0,52061,DB01036,Tolterodine
,19915829,terminal elimination half-life (T((1/2))),"The median time to reach maximum concentration (T(max)) was 5.0 h for both dosing regimens, and the mean terminal elimination half-life (T((1/2))) was 5.9 and 5.7 h for nighttime and daytime dosing, respectively.",The pharmacokinetic profile of fesoterodine 8 mg with daytime or nighttime dosing. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19915829/),h,5.9,52062,DB01036,Tolterodine
,19915829,terminal elimination half-life (T((1/2))),"The median time to reach maximum concentration (T(max)) was 5.0 h for both dosing regimens, and the mean terminal elimination half-life (T((1/2))) was 5.9 and 5.7 h for nighttime and daytime dosing, respectively.",The pharmacokinetic profile of fesoterodine 8 mg with daytime or nighttime dosing. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19915829/),h,5.7,52063,DB01036,Tolterodine
,21352267,urinary excretion,"Mean urinary excretion of 5-HMT following fesoterodine 4 and 8 mg, respectively, was 0.44 and 0.89 mg in EMs and 0.60 and 1.32 mg in PMs.",Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21352267/),mg,0.44,53675,DB01036,Tolterodine
,21352267,urinary excretion,"Mean urinary excretion of 5-HMT following fesoterodine 4 and 8 mg, respectively, was 0.44 and 0.89 mg in EMs and 0.60 and 1.32 mg in PMs.",Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21352267/),mg,0.89,53676,DB01036,Tolterodine
,21352267,urinary excretion,"Mean urinary excretion of 5-HMT following fesoterodine 4 and 8 mg, respectively, was 0.44 and 0.89 mg in EMs and 0.60 and 1.32 mg in PMs.",Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21352267/),mg,0.60,53677,DB01036,Tolterodine
,21352267,urinary excretion,"Mean urinary excretion of 5-HMT following fesoterodine 4 and 8 mg, respectively, was 0.44 and 0.89 mg in EMs and 0.60 and 1.32 mg in PMs.",Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21352267/),mg,1.32,53678,DB01036,Tolterodine
,11258043,Bioavailability,Bioavailability varied between 2-20% in rodents and 58-63% in the dog.,"Pharmacokinetics of tolterodine, a muscarinic receptor antagonist, in mouse, rat and dog. Interspecies relationship comparing with human pharmacokinetics. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11258043/),%,2-20,60401,DB01036,Tolterodine
,11258043,Bioavailability,Bioavailability varied between 2-20% in rodents and 58-63% in the dog.,"Pharmacokinetics of tolterodine, a muscarinic receptor antagonist, in mouse, rat and dog. Interspecies relationship comparing with human pharmacokinetics. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11258043/),%,58-63,60402,DB01036,Tolterodine
less,11258043,half-life,"The elimination of tolterodine from serum was rapid, with a half-life of less than 2 h in all species.","Pharmacokinetics of tolterodine, a muscarinic receptor antagonist, in mouse, rat and dog. Interspecies relationship comparing with human pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11258043/),h,2,60403,DB01036,Tolterodine
,11258043,clearance,"A very high clearance in the mouse and rat (10-15 l/h.kg), and in the dog (1.4 l/h.kg), indicated additional non-metabolic clearance mechanisms for tolterodine (shown to be attributed to biliary excretion).","Pharmacokinetics of tolterodine, a muscarinic receptor antagonist, in mouse, rat and dog. Interspecies relationship comparing with human pharmacokinetics. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11258043/),[l] / [h·kg],10-15,60404,DB01036,Tolterodine
,11258043,clearance,"A very high clearance in the mouse and rat (10-15 l/h.kg), and in the dog (1.4 l/h.kg), indicated additional non-metabolic clearance mechanisms for tolterodine (shown to be attributed to biliary excretion).","Pharmacokinetics of tolterodine, a muscarinic receptor antagonist, in mouse, rat and dog. Interspecies relationship comparing with human pharmacokinetics. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11258043/),[l] / [h·kg],1.4,60405,DB01036,Tolterodine
,11258043,Urinary excretion,"Urinary excretion of compound-related radioactive substance was around 15%, 45% and 50%, respectively, in the rat, mouse and dog.","Pharmacokinetics of tolterodine, a muscarinic receptor antagonist, in mouse, rat and dog. Interspecies relationship comparing with human pharmacokinetics. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11258043/),%,15,60406,DB01036,Tolterodine
,11258043,Urinary excretion,"Urinary excretion of compound-related radioactive substance was around 15%, 45% and 50%, respectively, in the rat, mouse and dog.","Pharmacokinetics of tolterodine, a muscarinic receptor antagonist, in mouse, rat and dog. Interspecies relationship comparing with human pharmacokinetics. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11258043/),%,45,60407,DB01036,Tolterodine
,11258043,Urinary excretion,"Urinary excretion of compound-related radioactive substance was around 15%, 45% and 50%, respectively, in the rat, mouse and dog.","Pharmacokinetics of tolterodine, a muscarinic receptor antagonist, in mouse, rat and dog. Interspecies relationship comparing with human pharmacokinetics. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11258043/),%,50,60408,DB01036,Tolterodine
,29403716,flow rate,"Chromatographic separation was performed on a Phenomenex ODS column (150 mm×4.6 mm, 5 μm) using linear gradient elution by a mobile phase consisting of methanol (A), and an aqueous solution containing 0.2% ammonium acetate and 0.1% formic acid (B) at a flow rate of 1 mL/min.",Precolumn derivatization LC-MS/MS method for the determination and pharmacokinetic study of glucosamine in human plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403716/),[ml] / [min],1,61707,DB01036,Tolterodine
,22853865,areas under the plasma concentration-time curves during the dosing interval (AUCτ),"The mean (SD) areas under the plasma concentration-time curves during the dosing interval (AUCτ) of the 4 mg and 8 mg dose groups were 26.1 (8.0) and 64.2 (30.5) μg·h/ml and the mean peak concentrations (Cmax) were 2.6 (0.7) and 6.0 (2.0) μg/ml, respectively, at steady-state.",Multiple-dose pharmacokinetics of fesoterodine sustained-release in healthy Korean volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22853865/),[h·μg] / [ml],26.1,86131,DB01036,Tolterodine
,22853865,areas under the plasma concentration-time curves during the dosing interval (AUCτ),"The mean (SD) areas under the plasma concentration-time curves during the dosing interval (AUCτ) of the 4 mg and 8 mg dose groups were 26.1 (8.0) and 64.2 (30.5) μg·h/ml and the mean peak concentrations (Cmax) were 2.6 (0.7) and 6.0 (2.0) μg/ml, respectively, at steady-state.",Multiple-dose pharmacokinetics of fesoterodine sustained-release in healthy Korean volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22853865/),[h·μg] / [ml],64.2,86132,DB01036,Tolterodine
,22853865,peak concentrations (Cmax),"The mean (SD) areas under the plasma concentration-time curves during the dosing interval (AUCτ) of the 4 mg and 8 mg dose groups were 26.1 (8.0) and 64.2 (30.5) μg·h/ml and the mean peak concentrations (Cmax) were 2.6 (0.7) and 6.0 (2.0) μg/ml, respectively, at steady-state.",Multiple-dose pharmacokinetics of fesoterodine sustained-release in healthy Korean volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22853865/),[μg] / [ml],2.6,86133,DB01036,Tolterodine
,22853865,peak concentrations (Cmax),"The mean (SD) areas under the plasma concentration-time curves during the dosing interval (AUCτ) of the 4 mg and 8 mg dose groups were 26.1 (8.0) and 64.2 (30.5) μg·h/ml and the mean peak concentrations (Cmax) were 2.6 (0.7) and 6.0 (2.0) μg/ml, respectively, at steady-state.",Multiple-dose pharmacokinetics of fesoterodine sustained-release in healthy Korean volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22853865/),[μg] / [ml],6.0,86134,DB01036,Tolterodine
,19566112,peak plasma concentrations,"Solifenacin peak plasma concentrations of 24.0 and 40.6 ng/mL are reached 3-8 hours after long-term oral administration of a 5 or 10 mg solifenacin dose, respectively.",Clinical pharmacokinetics and pharmacodynamics of solifenacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19566112/),[ng] / [ml],24.0,106255,DB01036,Tolterodine
,19566112,peak plasma concentrations,"Solifenacin peak plasma concentrations of 24.0 and 40.6 ng/mL are reached 3-8 hours after long-term oral administration of a 5 or 10 mg solifenacin dose, respectively.",Clinical pharmacokinetics and pharmacodynamics of solifenacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19566112/),[ng] / [ml],40.6,106256,DB01036,Tolterodine
,19566112,absolute bioavailability,"Studies in healthy adults have shown that the drug has high absolute bioavailability of about 90%, which does not decrease with concomitant food intake.",Clinical pharmacokinetics and pharmacodynamics of solifenacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19566112/),%,90,106257,DB01036,Tolterodine
,19566112,apparent volume of distribution,"Solifenacin has an apparent volume of distribution of 600 L, is 93-96% plasma protein bound, and probably crosses the blood-brain barrier.",Clinical pharmacokinetics and pharmacodynamics of solifenacin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19566112/),l,600,106258,DB01036,Tolterodine
,19566112,total clearance,"In healthy adults, total clearance of solifenacin amounts to 7-14 L/h.",Clinical pharmacokinetics and pharmacodynamics of solifenacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19566112/),[l] / [h],7-14,106259,DB01036,Tolterodine
,19566112,terminal elimination half-life,"The terminal elimination half-life ranges from 33 to 85 hours, permitting once-daily administration.",Clinical pharmacokinetics and pharmacodynamics of solifenacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19566112/),h,33 to 85,106260,DB01036,Tolterodine
,19566112,renal clearance,"Urinary excretion plays a minor role in the elimination of solifenacin, resulting in renal clearance of 0.67-1.51 L/h.",Clinical pharmacokinetics and pharmacodynamics of solifenacin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19566112/),[l] / [h],0.67-1.51,106261,DB01036,Tolterodine
,19269904,m/,"Quantification was through positive-ion mode and selected reaction monitoring at m/z 326-->147 for tolterodine, 342-->223 for the 5-hydroxymethyl metabolite and 260-->183 for the internal standard propranolol, respectively.",Determination of tolterodine and its 5-hydroxymethyl metabolite in human plasma by hydrophilic interaction liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19269904/),,326,111720,DB01036,Tolterodine
,19269904,m/,"Quantification was through positive-ion mode and selected reaction monitoring at m/z 326-->147 for tolterodine, 342-->223 for the 5-hydroxymethyl metabolite and 260-->183 for the internal standard propranolol, respectively.",Determination of tolterodine and its 5-hydroxymethyl metabolite in human plasma by hydrophilic interaction liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19269904/),,147,111721,DB01036,Tolterodine
,19269904,m/,"Quantification was through positive-ion mode and selected reaction monitoring at m/z 326-->147 for tolterodine, 342-->223 for the 5-hydroxymethyl metabolite and 260-->183 for the internal standard propranolol, respectively.",Determination of tolterodine and its 5-hydroxymethyl metabolite in human plasma by hydrophilic interaction liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19269904/),,342,111722,DB01036,Tolterodine
,19269904,m/,"Quantification was through positive-ion mode and selected reaction monitoring at m/z 326-->147 for tolterodine, 342-->223 for the 5-hydroxymethyl metabolite and 260-->183 for the internal standard propranolol, respectively.",Determination of tolterodine and its 5-hydroxymethyl metabolite in human plasma by hydrophilic interaction liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19269904/),,223,111723,DB01036,Tolterodine
,19269904,m/,"Quantification was through positive-ion mode and selected reaction monitoring at m/z 326-->147 for tolterodine, 342-->223 for the 5-hydroxymethyl metabolite and 260-->183 for the internal standard propranolol, respectively.",Determination of tolterodine and its 5-hydroxymethyl metabolite in human plasma by hydrophilic interaction liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19269904/),,260,111724,DB01036,Tolterodine
,29128914,retention time,"The retention time of tolterodine, 5-HMT, NDT, and internal standard (IS) were 1.4, 1.24, 1.33, and 1.26 min, respectively.","Simultaneous determination of tolterodine and its two metabolites, 5-hydroxymethyltolterodine and N-dealkyltolterodine in human plasma using LC-MS/MS and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29128914/),min,1.4,116462,DB01036,Tolterodine
,29128914,retention time,"The retention time of tolterodine, 5-HMT, NDT, and internal standard (IS) were 1.4, 1.24, 1.33, and 1.26 min, respectively.","Simultaneous determination of tolterodine and its two metabolites, 5-hydroxymethyltolterodine and N-dealkyltolterodine in human plasma using LC-MS/MS and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29128914/),min,1.24,116463,DB01036,Tolterodine
,29128914,retention time,"The retention time of tolterodine, 5-HMT, NDT, and internal standard (IS) were 1.4, 1.24, 1.33, and 1.26 min, respectively.","Simultaneous determination of tolterodine and its two metabolites, 5-hydroxymethyltolterodine and N-dealkyltolterodine in human plasma using LC-MS/MS and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29128914/),min,1.33,116464,DB01036,Tolterodine
,29128914,retention time,"The retention time of tolterodine, 5-HMT, NDT, and internal standard (IS) were 1.4, 1.24, 1.33, and 1.26 min, respectively.","Simultaneous determination of tolterodine and its two metabolites, 5-hydroxymethyltolterodine and N-dealkyltolterodine in human plasma using LC-MS/MS and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29128914/),min,1.26,116465,DB01036,Tolterodine
,23489517,maximum cumulative amount permeated in 24 hours (Q24),Permeation parameters were evaluated when maximum cumulative amount permeated in 24 hours (Q24) was 145.71 ± 2.00µg/cm² by CIT4 formulation over control (91.89 ± 2.30µg/cm²).,Synergistic effect of iontophoresis and chemical enhancers on transdermal permeation of tolterodine tartrate for the treatment of overactive bladder. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23489517/),[μg] / [cm²],145.71,122031,DB01036,Tolterodine
,23489517,maximum cumulative amount permeated in 24 hours (Q24),Permeation parameters were evaluated when maximum cumulative amount permeated in 24 hours (Q24) was 145.71 ± 2.00µg/cm² by CIT4 formulation over control (91.89 ± 2.30µg/cm²).,Synergistic effect of iontophoresis and chemical enhancers on transdermal permeation of tolterodine tartrate for the treatment of overactive bladder. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23489517/),[μg] / [cm²],91.89,122032,DB01036,Tolterodine
,19697106,Q(24),The microemulsion system (ME3) containing the highest amount of water (50%) significantly enhanced permeation with Q(24) of 0.746 mg.cm(-2).,Utility of nanosized microemulsion for transdermal delivery of tolterodine tartrate: ex-vivo permeation and in-vivo pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19697106/),[mg] / [(cm)^2],0.746,130983,DB01036,Tolterodine
,19697106,C(max),"In contrast to oral delivery, a sustained activity was observed over a period of 72 h after transdermal application of this microemulsion to human volunteers with significant lower C(max) (1.06 ng/ml), delayed T(max) (3.17 h) and higher MRT value (147.82 h) (p < 0.05).",Utility of nanosized microemulsion for transdermal delivery of tolterodine tartrate: ex-vivo permeation and in-vivo pharmacokinetic studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19697106/),[ng] / [ml],1.06,130984,DB01036,Tolterodine
,19697106,T(max),"In contrast to oral delivery, a sustained activity was observed over a period of 72 h after transdermal application of this microemulsion to human volunteers with significant lower C(max) (1.06 ng/ml), delayed T(max) (3.17 h) and higher MRT value (147.82 h) (p < 0.05).",Utility of nanosized microemulsion for transdermal delivery of tolterodine tartrate: ex-vivo permeation and in-vivo pharmacokinetic studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19697106/),h,3.17,130985,DB01036,Tolterodine
,19697106,MRT,"In contrast to oral delivery, a sustained activity was observed over a period of 72 h after transdermal application of this microemulsion to human volunteers with significant lower C(max) (1.06 ng/ml), delayed T(max) (3.17 h) and higher MRT value (147.82 h) (p < 0.05).",Utility of nanosized microemulsion for transdermal delivery of tolterodine tartrate: ex-vivo permeation and in-vivo pharmacokinetic studies. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19697106/),h,147.82,130986,DB01036,Tolterodine
,29403860,flow-rate,"Chromatographic separation was performed on Ascentis Express RP amide (50 mm×4.6 mm, 2.7 μm) column with an isocratic mobile phase composed of 10 mM ammonium acetate and acetonitrile in the ratio of 20:80 (v/v), at a flow-rate of 0.5 mL/min.",A validated LC-MS/MS method for the determination of tolterodine and its metabolite in rat plasma and application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403860/),[ml] / [min],0.5,137076,DB01036,Tolterodine
,19761716,AUC0-tz,"Mean AUC0-tz was 70.7 ng/ml x h in whites and 64.1 ng/ml x h in blacks; mean Cmax was 6.1 and 5.5 ng/ml in whites and blacks, respectively.","Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19761716/),[ng] / [h·ml],70.7,141349,DB01036,Tolterodine
,19761716,AUC0-tz,"Mean AUC0-tz was 70.7 ng/ml x h in whites and 64.1 ng/ml x h in blacks; mean Cmax was 6.1 and 5.5 ng/ml in whites and blacks, respectively.","Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19761716/),[ng] / [h·ml],64.1,141350,DB01036,Tolterodine
,19761716,Cmax,"Mean AUC0-tz was 70.7 ng/ml x h in whites and 64.1 ng/ml x h in blacks; mean Cmax was 6.1 and 5.5 ng/ml in whites and blacks, respectively.","Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19761716/),[ng] / [ml],6.1,141351,DB01036,Tolterodine
,19761716,Cmax,"Mean AUC0-tz was 70.7 ng/ml x h in whites and 64.1 ng/ml x h in blacks; mean Cmax was 6.1 and 5.5 ng/ml in whites and blacks, respectively.","Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19761716/),[ng] / [ml],5.5,141352,DB01036,Tolterodine
,19761716,AUC0-tz,"Mean AUC0-tz in young white men, elderly white men, and elderly white women was 49, 48, and 54 ng/ml x h, respectively; mean Cmax in young white men, elderly white men, and elderly white women was 4.1, 3.8, and 4.6 ng/ml, respectively.","Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19761716/),[ng] / [h·ml],49,141353,DB01036,Tolterodine
,19761716,AUC0-tz,"Mean AUC0-tz in young white men, elderly white men, and elderly white women was 49, 48, and 54 ng/ml x h, respectively; mean Cmax in young white men, elderly white men, and elderly white women was 4.1, 3.8, and 4.6 ng/ml, respectively.","Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19761716/),[ng] / [h·ml],48,141354,DB01036,Tolterodine
,19761716,AUC0-tz,"Mean AUC0-tz in young white men, elderly white men, and elderly white women was 49, 48, and 54 ng/ml x h, respectively; mean Cmax in young white men, elderly white men, and elderly white women was 4.1, 3.8, and 4.6 ng/ml, respectively.","Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19761716/),[ng] / [h·ml],54,141355,DB01036,Tolterodine
,19761716,Cmax,"Mean AUC0-tz in young white men, elderly white men, and elderly white women was 49, 48, and 54 ng/ml x h, respectively; mean Cmax in young white men, elderly white men, and elderly white women was 4.1, 3.8, and 4.6 ng/ml, respectively.","Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19761716/),[ng] / [ml],4.1,141356,DB01036,Tolterodine
,19761716,Cmax,"Mean AUC0-tz in young white men, elderly white men, and elderly white women was 49, 48, and 54 ng/ml x h, respectively; mean Cmax in young white men, elderly white men, and elderly white women was 4.1, 3.8, and 4.6 ng/ml, respectively.","Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19761716/),[ng] / [ml],3.8,141357,DB01036,Tolterodine
,19761716,Cmax,"Mean AUC0-tz in young white men, elderly white men, and elderly white women was 49, 48, and 54 ng/ml x h, respectively; mean Cmax in young white men, elderly white men, and elderly white women was 4.1, 3.8, and 4.6 ng/ml, respectively.","Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19761716/),[ng] / [ml],4.6,141358,DB01036,Tolterodine
,28725138,Peff,The optimized Peff ranged 1.44-68.3 × 10-4 cm/s for the drugs under investigation.,Comparative assessment of saliva and plasma for drug bioavailability and bioequivalence studies in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28725138/),[cm] / [s],1.44-68.3 × 10-4,142143,DB01036,Tolterodine
,28725138,Saliva/plasma concentrations ratios,Saliva/plasma concentrations ratios ranged 0.17-1.5.,Comparative assessment of saliva and plasma for drug bioavailability and bioequivalence studies in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28725138/),,0.17-1.5,142144,DB01036,Tolterodine
,22784220,Peff,"Estimated Peff ranged 0.16-44.16 × 10(-4) cm/s, while reported fraction unbound to plasma proteins (fu) ranged 0.01-0.99 for the drugs under investigation.",Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22784220/),[cm] / [s],0.16-44.16 × 10(-4),154149,DB01036,Tolterodine
,22784220,fraction unbound to plasma proteins (fu),"Estimated Peff ranged 0.16-44.16 × 10(-4) cm/s, while reported fraction unbound to plasma proteins (fu) ranged 0.01-0.99 for the drugs under investigation.",Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22784220/),,0.01-0.99,154150,DB01036,Tolterodine
,22784220,Saliva/plasma concentrations ratios,"Saliva/plasma concentrations ratios ranged 0.11-13.4, in agreement with drug protein binding and permeability.",Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22784220/),,0.11-13.4,154151,DB01036,Tolterodine
,27011385,saliva/plasma concentrations ratio,"A high pearsons correlation coefficient of 0.97 between mean saliva and plasma concentrations, and saliva/plasma concentrations ratio of 0.33 were observed.",Saliva versus Plasma Relative Bioavailability of Tolterodine in Humans: Validation of Class III Drugs of the Salivary Excretion Classification System. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27011385/),,0.33,156146,DB01036,Tolterodine
,16791583,log10,The mean log10(omeprazole/omeprazole sulfone) ratio was 0.18 3 h after intake of omeprazole alone.,Use of omeprazole sulfone in a single plasma sample as a probe for CYP3A4. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16791583/),,0.18,164111,DB01036,Tolterodine
,14606931,oral bioavailability,"In an unselected population, oral bioavailability of tolterodine ranges from 10% to 74% (mean 33%) whereas in CYP2D6 extensive metabolisers and poor metabolisers mean bioavailabilities are 26% and 91%, respectively.",Clinical pharmacokinetics of drugs used to treat urge incontinence. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606931/),%,10,171113,DB01036,Tolterodine
,14606931,oral bioavailability,"In an unselected population, oral bioavailability of tolterodine ranges from 10% to 74% (mean 33%) whereas in CYP2D6 extensive metabolisers and poor metabolisers mean bioavailabilities are 26% and 91%, respectively.",Clinical pharmacokinetics of drugs used to treat urge incontinence. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606931/),%,74,171114,DB01036,Tolterodine
,14606931,oral bioavailability,"In an unselected population, oral bioavailability of tolterodine ranges from 10% to 74% (mean 33%) whereas in CYP2D6 extensive metabolisers and poor metabolisers mean bioavailabilities are 26% and 91%, respectively.",Clinical pharmacokinetics of drugs used to treat urge incontinence. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606931/),%,33,171115,DB01036,Tolterodine
,14606931,bioavailabilities,"In an unselected population, oral bioavailability of tolterodine ranges from 10% to 74% (mean 33%) whereas in CYP2D6 extensive metabolisers and poor metabolisers mean bioavailabilities are 26% and 91%, respectively.",Clinical pharmacokinetics of drugs used to treat urge incontinence. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606931/),%,26,171116,DB01036,Tolterodine
,14606931,bioavailabilities,"In an unselected population, oral bioavailability of tolterodine ranges from 10% to 74% (mean 33%) whereas in CYP2D6 extensive metabolisers and poor metabolisers mean bioavailabilities are 26% and 91%, respectively.",Clinical pharmacokinetics of drugs used to treat urge incontinence. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606931/),%,91,171117,DB01036,Tolterodine
,14606931,Terminal disposition half-lives,"Terminal disposition half-lives of tolterodine and 5-hydroxymethyl-tolterodine (in CYP2D6 extensive metabolisers) are 2-3 and 3-4 hours, respectively.",Clinical pharmacokinetics of drugs used to treat urge incontinence. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606931/),h,2-3,171118,DB01036,Tolterodine
,14606931,Terminal disposition half-lives,"Terminal disposition half-lives of tolterodine and 5-hydroxymethyl-tolterodine (in CYP2D6 extensive metabolisers) are 2-3 and 3-4 hours, respectively.",Clinical pharmacokinetics of drugs used to treat urge incontinence. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606931/),h,3-4,171119,DB01036,Tolterodine
,30892436,m/z,"m/z 397.3→379.6, m/z 326.4→121.0 for mirabegron, tolterodine (IS), respectively in the positive ion mode was performed for quantitation.",Determination of Mirabegron in rat plasma by UPLC-MS/MS after oral and intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30892436/),,397.3,172567,DB01036,Tolterodine
,30892436,m/z,"m/z 397.3→379.6, m/z 326.4→121.0 for mirabegron, tolterodine (IS), respectively in the positive ion mode was performed for quantitation.",Determination of Mirabegron in rat plasma by UPLC-MS/MS after oral and intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30892436/),,379.6,172568,DB01036,Tolterodine
,30892436,m/z,"m/z 397.3→379.6, m/z 326.4→121.0 for mirabegron, tolterodine (IS), respectively in the positive ion mode was performed for quantitation.",Determination of Mirabegron in rat plasma by UPLC-MS/MS after oral and intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30892436/),,326.4,172569,DB01036,Tolterodine
,30892436,m/z,"m/z 397.3→379.6, m/z 326.4→121.0 for mirabegron, tolterodine (IS), respectively in the positive ion mode was performed for quantitation.",Determination of Mirabegron in rat plasma by UPLC-MS/MS after oral and intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30892436/),,121.0,172570,DB01036,Tolterodine
,29338933,Ki,The estimated in vivo Ki of ketoconazole for hepatic CYP3A4 (6.64 ng/mL) was consistent with the reported values.,Physiological based pharmacokinetic modeling to estimate in vivo Ki of ketoconazole on renal P-gp using human drug-drug interaction study result of fesoterodine and ketoconazole. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29338933/),[ng] / [ml],6.64,177393,DB01036,Tolterodine
,29338933,Ki,"The in vivo Ki of ketoconazole for renal P-gp was successfully estimated as 2.27 ng/mL, which was notably lower than reported in vitro 50% inhibitory concentration (IC50) values ranged 223-2440 ng/mL due to different condition between in vitro and in vivo.",Physiological based pharmacokinetic modeling to estimate in vivo Ki of ketoconazole on renal P-gp using human drug-drug interaction study result of fesoterodine and ketoconazole. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29338933/),[ng] / [ml],2.27,177394,DB01036,Tolterodine
,29338933,50% inhibitory concentration (IC50),"The in vivo Ki of ketoconazole for renal P-gp was successfully estimated as 2.27 ng/mL, which was notably lower than reported in vitro 50% inhibitory concentration (IC50) values ranged 223-2440 ng/mL due to different condition between in vitro and in vivo.",Physiological based pharmacokinetic modeling to estimate in vivo Ki of ketoconazole on renal P-gp using human drug-drug interaction study result of fesoterodine and ketoconazole. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29338933/),[ng] / [ml],223-2440,177395,DB01036,Tolterodine
,27789373,absolute bioavailability,The absolute bioavailability of 5-HMT hydrogels was 20.7% showed in pharmacokinetic study.,"Design of hydrogels of 5-hydroxymethyl tolterodine and their studies on pharmacokinetics, pharmacodynamics and transdermal mechanism. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27789373/),%,20.7,189720,DB01036,Tolterodine
higher,21310576,extraction recoveries,The extraction recoveries determined at three concentration levels were higher than 88.6%.,Application of a liquid chromatographic/tandem mass spectrometric method to a kinetic study of derivative glucosamine in healthy human urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21310576/),%,88.6,201409,DB01036,Tolterodine
,9630826,systemic clearance,"The mean systemic clearance of tolterodine was significantly lower (p < 0.001) among poor metabolizers (9.0 +/- 2.1 l/hr) compared with extensive metabolizers (44 +/- 13 L/hr), resulting in a fourfold longer elimination half-life (p < 0.001).",Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630826/),[l] / [h],9.0,210214,DB01036,Tolterodine
,9630826,systemic clearance,"The mean systemic clearance of tolterodine was significantly lower (p < 0.001) among poor metabolizers (9.0 +/- 2.1 l/hr) compared with extensive metabolizers (44 +/- 13 L/hr), resulting in a fourfold longer elimination half-life (p < 0.001).",Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630826/),[l] / [h],44,210215,DB01036,Tolterodine
,9630826,terminal half-life,"The terminal half-life of the 5-hydroxymethyl metabolite (2.9 +/- 0.4 hours) was slightly longer than that of the parent compound (2.3 +/- 0.6 hours) among extensive metabolizers, but the 5-hydroxymethyl metabolite was undetectable in the serum of poor metabolizers.",Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630826/),h,2.9,210216,DB01036,Tolterodine
,9630826,terminal half-life,"The terminal half-life of the 5-hydroxymethyl metabolite (2.9 +/- 0.4 hours) was slightly longer than that of the parent compound (2.3 +/- 0.6 hours) among extensive metabolizers, but the 5-hydroxymethyl metabolite was undetectable in the serum of poor metabolizers.",Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630826/),h,2.3,210217,DB01036,Tolterodine
,16043426,limit of detection (LOD),The limit of detection (LOD) was 0.05 ng/ml.,High performance liquid chromatography-electrospray ionization mass spectrometric determination of tolterodine tartrate in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16043426/),[ng] / [ml],0.05,219426,DB01036,Tolterodine
,11269570,relative bioavailability,"Based on Cmax and AUC(infinity) ratios, relative bioavailability of tolterodine in the presence of food was 1.49 (90% confidence interval [CI], 1.35-1.71) and 1.53 (1.35-1.72), respectively.",Food increases the bioavailability of tolterodine but not effective exposure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11269570/),,1.49,238499,DB01036,Tolterodine
,11269570,relative bioavailability,"Based on Cmax and AUC(infinity) ratios, relative bioavailability of tolterodine in the presence of food was 1.49 (90% confidence interval [CI], 1.35-1.71) and 1.53 (1.35-1.72), respectively.",Food increases the bioavailability of tolterodine but not effective exposure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11269570/),,1.53,238500,DB01036,Tolterodine
,34101369,maximum/minimum concentration,"For the oral formulation, peak-trough fluctuations of tolterodine, 5-HMT, and AM plasma concentrations (AM: mean maximum/minimum concentration, 2580/574 pmol/L = 4.5) were large.","Intravaginal Tolterodine Formulation Intended for Overactive Bladder Treatment-Results of a Pharmacokinetic Phase I Pilot Study in Healthy, Postmenopausal Women. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34101369/),[pM] / [l],2580,242075,DB01036,Tolterodine
,34101369,maximum/minimum concentration,"For the oral formulation, peak-trough fluctuations of tolterodine, 5-HMT, and AM plasma concentrations (AM: mean maximum/minimum concentration, 2580/574 pmol/L = 4.5) were large.","Intravaginal Tolterodine Formulation Intended for Overactive Bladder Treatment-Results of a Pharmacokinetic Phase I Pilot Study in Healthy, Postmenopausal Women. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34101369/),[pM] / [l],574,242076,DB01036,Tolterodine
,34101369,maximum/minimum concentration,"For the oral formulation, peak-trough fluctuations of tolterodine, 5-HMT, and AM plasma concentrations (AM: mean maximum/minimum concentration, 2580/574 pmol/L = 4.5) were large.","Intravaginal Tolterodine Formulation Intended for Overactive Bladder Treatment-Results of a Pharmacokinetic Phase I Pilot Study in Healthy, Postmenopausal Women. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34101369/),[pM] / [l],4.5,242077,DB01036,Tolterodine
,34101369,maximum/minimum concentration,"Intravaginal application led to steadier plasma concentrations (AM, test 3: mean maximum/minimum concentration, 1880/814 pmol/L = 2.3; fluctuation due to initial peak), which is the result of constant releasing rates after ring insertion over the 28-day application period.","Intravaginal Tolterodine Formulation Intended for Overactive Bladder Treatment-Results of a Pharmacokinetic Phase I Pilot Study in Healthy, Postmenopausal Women. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34101369/),[pM] / [l],1880,242078,DB01036,Tolterodine
,34101369,maximum/minimum concentration,"Intravaginal application led to steadier plasma concentrations (AM, test 3: mean maximum/minimum concentration, 1880/814 pmol/L = 2.3; fluctuation due to initial peak), which is the result of constant releasing rates after ring insertion over the 28-day application period.","Intravaginal Tolterodine Formulation Intended for Overactive Bladder Treatment-Results of a Pharmacokinetic Phase I Pilot Study in Healthy, Postmenopausal Women. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34101369/),[pM] / [l],814,242079,DB01036,Tolterodine
,34101369,maximum/minimum concentration,"Intravaginal application led to steadier plasma concentrations (AM, test 3: mean maximum/minimum concentration, 1880/814 pmol/L = 2.3; fluctuation due to initial peak), which is the result of constant releasing rates after ring insertion over the 28-day application period.","Intravaginal Tolterodine Formulation Intended for Overactive Bladder Treatment-Results of a Pharmacokinetic Phase I Pilot Study in Healthy, Postmenopausal Women. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34101369/),[pM] / [l],2.3,242080,DB01036,Tolterodine
,24882035,cumulative drug release rate,The measured 24 h cumulative drug release rate (86.02%) was consistent with the predicted value (85.42%) in mice.,Design of transparent film-forming hydrogels of tolterodine and their effects on stratum corneum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24882035/),%,86.02,243398,DB01036,Tolterodine
,24882035,cumulative drug release rate,The measured 24 h cumulative drug release rate (86.02%) was consistent with the predicted value (85.42%) in mice.,Design of transparent film-forming hydrogels of tolterodine and their effects on stratum corneum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24882035/),%,85.42,243399,DB01036,Tolterodine
,24882035,Steady-state flux (J),"Steady-state flux (J) of tolterodine in optimized formulation across rat full skin, epidermal, dermis and subcutaneous tissue were 15.83, 18.55, 37.15 and 81.82 μg cm(-2) h(-1), respectively.",Design of transparent film-forming hydrogels of tolterodine and their effects on stratum corneum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24882035/),[μg] / [(cm)^2·h],15.83,243400,DB01036,Tolterodine
,24882035,Steady-state flux (J),"Steady-state flux (J) of tolterodine in optimized formulation across rat full skin, epidermal, dermis and subcutaneous tissue were 15.83, 18.55, 37.15 and 81.82 μg cm(-2) h(-1), respectively.",Design of transparent film-forming hydrogels of tolterodine and their effects on stratum corneum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24882035/),[μg] / [(cm)^2·h],18.55,243401,DB01036,Tolterodine
,24882035,Steady-state flux (J),"Steady-state flux (J) of tolterodine in optimized formulation across rat full skin, epidermal, dermis and subcutaneous tissue were 15.83, 18.55, 37.15 and 81.82 μg cm(-2) h(-1), respectively.",Design of transparent film-forming hydrogels of tolterodine and their effects on stratum corneum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24882035/),[μg] / [(cm)^2·h],37.15,243402,DB01036,Tolterodine
,24882035,Steady-state flux (J),"Steady-state flux (J) of tolterodine in optimized formulation across rat full skin, epidermal, dermis and subcutaneous tissue were 15.83, 18.55, 37.15 and 81.82 μg cm(-2) h(-1), respectively.",Design of transparent film-forming hydrogels of tolterodine and their effects on stratum corneum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24882035/),[μg] / [(cm)^2·h],81.82,243403,DB01036,Tolterodine
,24882035,Ea,"Fourier transform infrared spectroscopy (FTIR) and differential scanning calorimetry (DSC) results suggested that the hydrogels could impact lipid status in SC, which was consistent with Ea (8.638 kcal/mol) of tolterodine from optimized formulation in rats.",Design of transparent film-forming hydrogels of tolterodine and their effects on stratum corneum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24882035/),[kcal] / [mol],8.638,243404,DB01036,Tolterodine
,24882035,absolute bioavailability,"In the pharmacokinetic studies, sustained-release over 24 h and absolute bioavailability of the hydrogels (24.53%) was higher than tolterodine tablets (15.16%) in rats.",Design of transparent film-forming hydrogels of tolterodine and their effects on stratum corneum. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24882035/),%,24.53,243405,DB01036,Tolterodine
,24882035,absolute bioavailability,"In the pharmacokinetic studies, sustained-release over 24 h and absolute bioavailability of the hydrogels (24.53%) was higher than tolterodine tablets (15.16%) in rats.",Design of transparent film-forming hydrogels of tolterodine and their effects on stratum corneum. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24882035/),%,15.16,243406,DB01036,Tolterodine
,19347334,maximum concentration in plasma (C(max),"Compared with fesoterodine alone, coadministration of fesoterodine with ketoconazole resulted in increases in mean 5-HMT maximum concentration in plasma (C(max); from 3.0 to 6.0 ng/mL in EMs and from 6.4 to 13.4 ng/mL in PMs) and mean area under the plasma concentration time curve (AUC; from 38.2 to 88.3 ng h/mL in EMs and 88.3 to 217.2 ng h/mL in PMs).",Evaluation of drug-drug interactions with fesoterodine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[ng] / [ml],3.0 to 6.0,244163,DB01036,Tolterodine
,19347334,maximum concentration in plasma (C(max),"Compared with fesoterodine alone, coadministration of fesoterodine with ketoconazole resulted in increases in mean 5-HMT maximum concentration in plasma (C(max); from 3.0 to 6.0 ng/mL in EMs and from 6.4 to 13.4 ng/mL in PMs) and mean area under the plasma concentration time curve (AUC; from 38.2 to 88.3 ng h/mL in EMs and 88.3 to 217.2 ng h/mL in PMs).",Evaluation of drug-drug interactions with fesoterodine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[ng] / [ml],6.4 to 13.4,244164,DB01036,Tolterodine
,19347334,area under the plasma concentration time curve (AUC,"Compared with fesoterodine alone, coadministration of fesoterodine with ketoconazole resulted in increases in mean 5-HMT maximum concentration in plasma (C(max); from 3.0 to 6.0 ng/mL in EMs and from 6.4 to 13.4 ng/mL in PMs) and mean area under the plasma concentration time curve (AUC; from 38.2 to 88.3 ng h/mL in EMs and 88.3 to 217.2 ng h/mL in PMs).",Evaluation of drug-drug interactions with fesoterodine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[h·ng] / [ml],38.2 to 88.3,244165,DB01036,Tolterodine
,19347334,area under the plasma concentration time curve (AUC,"Compared with fesoterodine alone, coadministration of fesoterodine with ketoconazole resulted in increases in mean 5-HMT maximum concentration in plasma (C(max); from 3.0 to 6.0 ng/mL in EMs and from 6.4 to 13.4 ng/mL in PMs) and mean area under the plasma concentration time curve (AUC; from 38.2 to 88.3 ng h/mL in EMs and 88.3 to 217.2 ng h/mL in PMs).",Evaluation of drug-drug interactions with fesoterodine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[h·ng] / [ml],88.3 to 217.2,244166,DB01036,Tolterodine
,19347334,C(max),Coadministration of festerodine with rifampicin resulted in decreases in mean 5-HMT C(max) (from 5.2 to 1.5 ng/mL in EMs and from 6.8 to 1.9 ng/mL in PMs) and mean AUC (from 62.4 to 14.4 ng h/mL in EMs and from 87.8 to 19.6 ng h/mL in PMs).,Evaluation of drug-drug interactions with fesoterodine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[ng] / [ml],5.2 to 1.5,244167,DB01036,Tolterodine
,19347334,C(max),Coadministration of festerodine with rifampicin resulted in decreases in mean 5-HMT C(max) (from 5.2 to 1.5 ng/mL in EMs and from 6.8 to 1.9 ng/mL in PMs) and mean AUC (from 62.4 to 14.4 ng h/mL in EMs and from 87.8 to 19.6 ng h/mL in PMs).,Evaluation of drug-drug interactions with fesoterodine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[ng] / [ml],6.8 to 1.9,244168,DB01036,Tolterodine
,19347334,AUC,Coadministration of festerodine with rifampicin resulted in decreases in mean 5-HMT C(max) (from 5.2 to 1.5 ng/mL in EMs and from 6.8 to 1.9 ng/mL in PMs) and mean AUC (from 62.4 to 14.4 ng h/mL in EMs and from 87.8 to 19.6 ng h/mL in PMs).,Evaluation of drug-drug interactions with fesoterodine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[h·ng] / [ml],62.4 to 14.4,244169,DB01036,Tolterodine
,19347334,AUC,Coadministration of festerodine with rifampicin resulted in decreases in mean 5-HMT C(max) (from 5.2 to 1.5 ng/mL in EMs and from 6.8 to 1.9 ng/mL in PMs) and mean AUC (from 62.4 to 14.4 ng h/mL in EMs and from 87.8 to 19.6 ng h/mL in PMs).,Evaluation of drug-drug interactions with fesoterodine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[h·ng] / [ml],87.8 to 19.6,244170,DB01036,Tolterodine
,23891744,steady-state speed,Tolterodine permeated at the steady-state speed of 770.19 μg cm(-2)h(-1) and its release coincided with Higuchi Equation.,"Preparation, characterization and pharmacological evaluation of tolterodine hydrogels for the treatment of overactive bladder. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23891744/),[μg] / [(cm)^2],770.19,245212,DB01036,Tolterodine
,23891744,absolute bioavailability,The absolute bioavailability of tolterodine was 11.47%.,"Preparation, characterization and pharmacological evaluation of tolterodine hydrogels for the treatment of overactive bladder. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23891744/),%,11.47,245213,DB01036,Tolterodine
,19446762,steady-state plasma concentrations,"The mean steady-state plasma concentrations after applying patches without enhancer or with l-menthol and M-OA as enhancers were 0.89, 0.84 and 1.47 microg/mL, respectively.",Transdermal delivery of tolterodine by O-acylmenthol: In vitro/in vivo correlation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446762/),[μg] / [ml],0.89,246053,DB01036,Tolterodine
,19446762,steady-state plasma concentrations,"The mean steady-state plasma concentrations after applying patches without enhancer or with l-menthol and M-OA as enhancers were 0.89, 0.84 and 1.47 microg/mL, respectively.",Transdermal delivery of tolterodine by O-acylmenthol: In vitro/in vivo correlation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446762/),[μg] / [ml],0.84,246054,DB01036,Tolterodine
,19446762,steady-state plasma concentrations,"The mean steady-state plasma concentrations after applying patches without enhancer or with l-menthol and M-OA as enhancers were 0.89, 0.84 and 1.47 microg/mL, respectively.",Transdermal delivery of tolterodine by O-acylmenthol: In vitro/in vivo correlation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446762/),[μg] / [ml],1.47,246055,DB01036,Tolterodine
,22126709,steady-state concentration,"Comparison of the pharmacokinetic parameters between two types of patches showed that the steady-state concentration of silicone type patch was 2-fold higher than that of acrylic type patch being 0.97 mg/L versus 0.49 mg/L, and the absolute bioavailability was 27.5% for silicone type patch and 6.3% for acrylic type patch, respectively.","Silicone adhesive, a better matrix for tolterodine patches-a research based on in vitro/in vivo studies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22126709/),[mg] / [l],0.97,256321,DB01036,Tolterodine
,22126709,steady-state concentration,"Comparison of the pharmacokinetic parameters between two types of patches showed that the steady-state concentration of silicone type patch was 2-fold higher than that of acrylic type patch being 0.97 mg/L versus 0.49 mg/L, and the absolute bioavailability was 27.5% for silicone type patch and 6.3% for acrylic type patch, respectively.","Silicone adhesive, a better matrix for tolterodine patches-a research based on in vitro/in vivo studies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22126709/),[mg] / [l],0.49,256322,DB01036,Tolterodine
,22126709,absolute bioavailability,"Comparison of the pharmacokinetic parameters between two types of patches showed that the steady-state concentration of silicone type patch was 2-fold higher than that of acrylic type patch being 0.97 mg/L versus 0.49 mg/L, and the absolute bioavailability was 27.5% for silicone type patch and 6.3% for acrylic type patch, respectively.","Silicone adhesive, a better matrix for tolterodine patches-a research based on in vitro/in vivo studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22126709/),%,27.5,256323,DB01036,Tolterodine
,22126709,absolute bioavailability,"Comparison of the pharmacokinetic parameters between two types of patches showed that the steady-state concentration of silicone type patch was 2-fold higher than that of acrylic type patch being 0.97 mg/L versus 0.49 mg/L, and the absolute bioavailability was 27.5% for silicone type patch and 6.3% for acrylic type patch, respectively.","Silicone adhesive, a better matrix for tolterodine patches-a research based on in vitro/in vivo studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22126709/),%,6.3,256324,DB01036,Tolterodine
,10583027,apparent oral clearance,"A decrease (P<0.01) in apparent oral clearance of tolterodine, from 10- 12 l h-1 to 4.3-4.7 l h-1, was obtained during concomitant administration of ketoconazole, yielding at least a two-fold increase in the area under the serum concentration-time curve after single as well as after multiple doses following single dose administration of tolterodine.",Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10583027/),[l] / [h],10- 12,263027,DB01036,Tolterodine
,10583027,apparent oral clearance,"A decrease (P<0.01) in apparent oral clearance of tolterodine, from 10- 12 l h-1 to 4.3-4.7 l h-1, was obtained during concomitant administration of ketoconazole, yielding at least a two-fold increase in the area under the serum concentration-time curve after single as well as after multiple doses following single dose administration of tolterodine.",Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10583027/),[l] / [h],4.3-4.7,263028,DB01036,Tolterodine
,10583027,terminal half-life,The mean (+/-s.d.) terminal half-life increased by 50% from 9.7+/-2.7 h to 15+/-5.4 h in the presence of ketoconazole.,Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10583027/),h,9.7,263029,DB01036,Tolterodine
,10583027,terminal half-life,The mean (+/-s.d.) terminal half-life increased by 50% from 9.7+/-2.7 h to 15+/-5.4 h in the presence of ketoconazole.,Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10583027/),h,15,263030,DB01036,Tolterodine
>,23266359,extraction recovery,The intra-batch and inter-batch precision (% CV) across quality control levels varied from 1.82 to 3.73% and the mean extraction recovery was >96% for both the analytes.,Investigation of ex vivo stability of fesoterodine in human plasma and its simultaneous determination together with its active metabolite 5-HMT by LC-ESI-MS/MS: Application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266359/),%,96,267674,DB01036,Tolterodine
,19246724,time of observed maximum drug concentration,The median time of observed maximum drug concentration (5-6 hours) and mean terminal half-life (6-7 hours) of 5-HMT are unaffected by renal impairment.,Assessment of the effects of renal impairment on the pharmacokinetic profile of fesoterodine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19246724/),h,5-6,272106,DB01036,Tolterodine
,19246724,terminal half-life,The median time of observed maximum drug concentration (5-6 hours) and mean terminal half-life (6-7 hours) of 5-HMT are unaffected by renal impairment.,Assessment of the effects of renal impairment on the pharmacokinetic profile of fesoterodine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19246724/),h,6-7,272107,DB01036,Tolterodine
,19246724,unbound fraction,The unbound fraction of 5-HMT in plasma (0.43-0.54 ng/mL) is comparable across all groups.,Assessment of the effects of renal impairment on the pharmacokinetic profile of fesoterodine. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19246724/),[ng] / [ml],0.43-0.54,272108,DB01036,Tolterodine
